Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: Correlation between immunohistochemistry and fluorescence in situ hybridization

Archives of Pathology and Laboratory Medicine

Volumn 135, Issue 11, 2011, Pages 1460-1465

  Tafe, Laura J ^a,c   Janjigian, Yelena Y ^a   Zaidinski, Michael ^a   Hedvat, Cyrus V ^a   Hameed, Meera R ^a   Tang, Laura H ^a   Hicks, James B ^b   Shah, Manish A ^a   Barbashina, Violetta ^a,d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ESOPHAGUS TUMOR; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LOWER ESOPHAGUS SPHINCTER; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 82555194531     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2010-0541-OA     Document Type: Article

References (19)

1. World Health Organization. Cancer: fact sheet 297. Published 2009. http://www.who.int/mediacenter/factsheets/fs297. Accessed June 20, 2010.
2. Power DG, Kelsen DP, Shah M.A. Advanced gastric cancer-slow but steady progress. Cancer Treat Rev. 2010; 36(5): 384-392.
3. Jorgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology. 2010; 78(1): 26-33.
4. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008; 52(7): 797-805. (Pubitemid 351724903)
5. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008; 19(9): 1523-1529.
6. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet. 2010; 376(9742): 687-697.
7. Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 2009; 40(6): 769-777.
8. Kim M.A., Jung EJ, Lee HS, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol. 2007; 38(9): 1386-1393. (Pubitemid 47247482)
9. Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line HER2-positive advanced gastric cancer [abstract]. J Clin Oncol. 2009; 27(18) (suppl): LBA4509.
10. Zhang XL, Yang YS, Xu DP, et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg. 2009; 33(10): 2112-2118.
11. Yano T, Doi T, Ohtsu A, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep. 2006; 15(1): 65-71.
12. Takehana T, Kunitomo K, Kono K, et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer. 2002; 98(6): 833-837. (Pubitemid 34286677)
13. Ruschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010; 457(3): 299-307.
14. Barros-Silva JD, Leitao D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer. 2009; 100(3): 487-493.
15. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25(1): 118-145. (Pubitemid 350003059)
16. Hammond EH, Wolff AC, Hayes DF, Schwartz JN. Reply to G. Sauter et al. J Clin Oncol. 2009; 27(30): e153-e154; author reply e155-e157.
17. Nakhleh RE, Grimm EE, Idowu MO, Souers RJ, Fitzgibbons PL. Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists guidelines for human epidermal growth factor receptor 2 (HER2) testing: a College of American Pathologists survey of 757 laboratories. Arch Pathol Lab Med. 2010; 134(5): 728-734.
18. Shah M.A., Kelsen DP. Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw. 2010; 8(4): 437-447.
19. Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med. 2009; 133(4): 611-612.